Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors.

Article Details

Citation

Copy to clipboard

Li B, Pai R, Cardinale SC, Butler MM, Peet NP, Moir DT, Bavari S, Bowlin TL

Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors.

J Med Chem. 2010 Mar 11;53(5):2264-76. doi: 10.1021/jm901852f.

PubMed ID

20155918 [ View in PubMed

]

Abstract

NSC 240898 was previously identified as a botulinum neurotoxin A light chain (BoNT/A LC) endopeptidase inhibitor by screening the National Cancer Institute Open Repository diversity set. Two types of analogues have been synthesized and shown to inhibit BoNT/A LC in a FRET-based enzyme assay, with confirmation in an HPLC-based assay. These two series of compounds have also been evaluated for inhibition of anthrax lethal factor (LF), an unrelated metalloprotease, to examine enzyme specificity of the BoNT/A LC inhibition. The most potent inhibitor against BoNT/A LC in these two series is compound 12 (IC(50) = 2.5 microM, FRET assay), which is 4.4-fold more potent than the lead structure and 11.2-fold more selective for BoNT/A LC versus the anthrax LF metalloproteinase. Structure-activity relationship studies have revealed structural features important to potency and enzyme specificity.

DrugBank Data that Cites this Article

Binding Properties

Drug	Target	Property	Measurement	pH	Temperature (°C)
(2E)-3-(2,4-DICHLOROPHENYL)-N-HYDROXYACRYLAMIDE	Botulinum neurotoxin type A	Ki (nM)	300	N/A	N/A	Details
(2E)-3-(2,4-DICHLOROPHENYL)-N-HYDROXYACRYLAMIDE	Botulinum neurotoxin type A	IC 50 (nM)	410	N/A	N/A	Details